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Abstract 
Metacognition refers to the activities which allow for the availability of a sense of oneself and 
others in the moment. Research mostly in North America with English-speaking samples has 
suggested that metacognitive deficits are present in schizophrenia and are closely tied to negative 
symptoms. Thus, replication is needed in other cultures and groups. The present study 
accordingly sought to replicate these findings in a Spanish speaking sample from Chile. 
Metacognition and symptoms were assessed among 26 patients with schizophrenia, 26 with 
bipolar disorder and 36 community members without serious mental illness. ANCOVA 
controlling for age and education revealed that the schizophrenia group had greater levels of 
metacognitive deficits than the bipolar disorder and community control groups. Differences in 
metacognition between the clinical groups persisted after controlling for symptom levels. 
Spearman correlations revealed a unique pattern of associations of metacognition with negative 
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Highlights  
 Metacognitive deficits were found in a sample of Chilean patients with schizophrenia   
 Metacognitive deficits were greater in schizophrenia than in bipolar disorder 
 Metacognitive deficits were correlated with negative symptoms in schizophrenia 
 The presence of metacognitive deficits and their associations with outcomes may occur 
cross culturally  
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and cognitive symptoms. Results largely support previous findings and provide added evidence 
of the metacognitive deficits present in schizophrenia and liked to outcome cross culturally. 
Implications for developing metacognitively oriented interventions are discussed.   
 
Key words: schizophrenia, metacognition, social cognition, recovery, negative symptoms 
1. Introduction 
Recovery from schizophrenia requires that persons make sense of challenges related to 
their psychiatric condition and accordingly decide how best to move towards wellness 
(Leonhardt et al., 2017). One potential barrier to recovery, however, is deficits in metacognition 
(Dimaggio and Lysaker, 2015; Lysaker and Klion, 2007). The term metacognition initially 
referred to cognitions about other cognition (Flavel, 1979), and a broader integrative model of 
metacognition has emerged (Lysaker et al., 2018). Specifically, as metacognition has been 
studied in educational, cognitive, developmental and abnormal psychology (e.g. Semerari et al., 
2003; Taricone, 2011), it has been proposed that metacognition refers to the processes which 
allow persons to have an integrated sense of themselves and others available in the moment. This 
integrative model proposes that these metacognitive processes comprise a spectrum of activities 
which, at one end, enable a basic awareness of embodied self-experiences, and at the other, allow 
their reflective integration into an extended sense of self and others (Lysaker and Dimaggio, 
2014; Lysaker et al., 2018). The activities that take place on the different ends of the spectrum 
influence one another continuously and allow for the availability of a sense of oneself and others 
in the moment, which in turn allow persons to determine what is uniquely adaptive for them. 
Theoretically intact metacognitive capacities are essential for dealing with unexpected or 
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ambiguous situations in more than a stereotyped or rigid way and allow responses which can be 
thoughtful, strategic, introspective and imaginative. 
Deficits in metacognition may be a barrier to recovery when they impede persons from 
developing a unique sense of what illness and wellness mean to them. This impoverished sense 
of illness and wellness in turn prevents individuals from determining what steps they could take 
that would lead to a fulfilling life for them, one in which they have a sense of direct immersion 
and participation in the world and with others (Lysaker and Klion, 2017). To date, research has 
found that many individuals in both earlier and later phases of schizophrenia struggle to form 
complex senses of self and others (Hasson-Ohayon et al., 2015; Lysaker et al., 2014; Masse and 
Lecomte, 2015; Trauelsen et al., 2016; Vohs et al., 2014). Relatively poorer metacognitive 
functioning has also been linked to poorer outcomes (Arnon-Ribenfeld, 2017), including lesser 
abilities to reject stigma (Nabors et al., 2014), seek social support (Kukla et al., 2014), function 
successfully in a work setting (Lysaker et al., 2010), cohesively link life events (Willits et al., in 
press), and experience intrinsic motivation (Luther et al., 2016; 2017). Lower levels of 
metacognition have also been associated with greater difficulties acknowledging psychosocial 
challenges (Lysaker et al., 2011; Vohs et al., 2016) and greater duration of untreated psychosis 
(Jansen et al., 2017). 
While these insights have led to the development of metacognitive treatment approaches 
(Hasson-Ohayon et al., 2017a; Leonhardt et al., 2017; Lysaker and Klion, 2017), most of the 
work on metacognition in schizophrenia has taken place in North America with English-speaking 
samples. Replication is needed with more diverse samples that include individuals from other 
cultures, as cultural history and linguistic differences may potentially affect how persons 
integrate and use information about themselves and others. The current study thus sought to 
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replicate previous findings in a sample of Spanish speaking schizophrenia patients from Chile. 
We predicted that they would demonstrate greater levels of metacognitive deficits than 
individuals with bipolar disorder and community controls without mental illness. Consistent with 
this, Tas et al. (2014) and Popolo et al. (2017) have found greater metacognitive deficits in 
schizophrenia patients relative to patients with bipolar disorder in Turkish and Italian samples 
and Hasson-Ohayon et al. (2015) and Popolo et al. (2017) found greater metacognitive deficits in  
schizophrenia patients relative to community controls in Israeli and Italian samples. Inchausti 
and colleagues (2017a; 2017b) have also found the metacognitive capacities of patients with 
schizophrenia to be more impaired than those of patients with anxiety and substance use 
disorders in a Spanish speaking sample from Spain.  
We also sought to replicate previous findings that metacognitive capacity would be 
related to higher levels of negative and cognitive symptoms (Hamm, 2012; Lysaker et al., 2005; 
Trauelsen et al., 2016). Previous research has suggested that cognitive symptoms may contribute 
to metacognitive deficits (Minor et al., 2014) while metacognitive deficits may be a risk factor 
for the development of negative symptoms (Lysaker et al., 2015; Mcleod et al., 2014). In 
particular, it is possible that negative symptoms are in part not truly primary phenomena, but 
instead are consequences of interpersonal difficulties rooted in metacognitive deficits or failures 
to form integrated ideas about self and other.  
We also assessed self-reported levels of empathy, to rule out the possibility we were not 
merely assessing this related but not identical phenomenon. Empathy has been identified as a 
related construct to the current conceptualization of social cognition in schizophrenia (Pinkham 
et al., 2013), and has been cited elsewhere as a fundamental social cognitive concept (Corbera et 
al., 2013). Some researchers use terms such as metacognition and empathy interchangeably, but 
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there is a distinction to be made between experiencing one’s self as distinct from the other 
(metacognition) and sharing another’s affective and cognitive states (Hasson-Ohayon et al., 
2009).  
 
2. Methods 
2.1 Participants 
Participants were 88 adults diagnosed with bipolar disorder (n = 26), a schizophrenia 
spectrum disorder (n = 26), and a group of healthy control participants (n = 36). Both clinical 
samples were comprised of adults in a non-acute phase of illness who regularly attend treatment 
and were recruited from a Public Health Hospital in Santiago de Chile. Diagnoses of 
schizophrenia and bipolar disorder were determined according to ICD-10 by the treating medical 
staff following a standard diagnostic clinical interview that included personal, clinical and 
medical history and chart review. Further demographic information is included in Table 1. 
Exclusion criteria for the clinical samples were the presence of a cognitive impairment such that 
informed consent could not be attained due to a failure to be able to understand the study 
purposes and procedures, neurological disorders, drug abuse in the last 3 months, and 
hospitalizations or medication changes in the last 3 months, all determined by the clinical 
interview and thorough chart review. The non-clinical sample was recruited through 
advertisements in local media; participants underwent a structured interview to exclude any 
major mental disorders, drug or alcohol addiction or neurological condition. 
2.2 Instruments 
2.2.1 Indiana Psychiatric Illness Interview (IPII; Lysaker et al., 2002). The IPII is a 
semi-structured interview that asks participants to describe their understanding of their mental 
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illness and psychological challenges. The protocol for participants with vs. without mental illness 
differed somewhat from each other. First, all participants are asked to tell the story of their lives. 
Participants diagnosed with a mental illness were then asked whether they believed they have a 
mental illness, and about problems related to this, as well as how they felt about having a mental 
illness. The next set of questions concern how things may have changed since having a mental 
illness, such as cognitions, emotions, personality characteristics and psychosocial function. Next, 
participants with mental illness were asked about how they controlled their mental illness and in 
what ways it controlled their lives. Participants with mental illness were then asked how their 
condition both affects and is affected by others. Finally, participants are asked what may be the 
same or different for them in the future. Participants without a mental illness, were asked the 
same series of questions, however, by contrast, in place of being asked about a mental illness 
they were asked about an emotionally or psychologically challenging situation in the last several 
years. This involved asking them about problems related to an emotionally or psychologically 
challenging situation, as well as how they feel about having experienced this situation. The next 
set of questions concerned how things may have changed since this situation, such as cognitions, 
emotions, personality characteristics and psychosocial function. Next, participants without 
mental illness are asked about how they controlled that situation and in what ways it controlled 
their lives. Participants without mental illness were then asked how that situation both affects 
and is affected by others. Finally, participants are asked what may be the same or different for 
them in the future. Interviews are audiotaped at the time of the interview and are later transcribed. 
Interviews typically last for 30 to 60 minutes and are conducted by trained research assistants.  
2.2.2. Metacognition Assessment Scale-Abbreviated (MAS-A; Lysaker et al., 2005). The 
MAS-A is a rating scale used to assess the kinds of metacognitive capacities that enable an 
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integrated sense of self and others to be available to persons within the flow of life. The MAS-A 
was adapted on the basis of the original instrument, the Metacognitive Assessment Scale 
(Semerari et al., 2003) for use in studying metacognition in IPII transcripts (Lysaker et al., 2005). 
The MAS-A retained the original distinctions offered by Semerari et al. (2003) regarding the 
different domains of metacognition and so contained four scales: Self-reflectivity (S; with scores 
ranging from 0 to 9), Understanding other’s minds (O; with scores ranging from 0 to 7), 
Decentration (D; with scores ranging from 0 to 3), and Mastery (M; with scores ranging from 0 
to 9). Each of these scales is distinguished from each other on the basis of the foci of the 
metacognitive acts they are concerned with. S pertains to an integrated sense of oneself, O to an 
integrated sense of specific others, D to an integrated sense of one’s place in one community, and 
M to the ability to use an increasingly complex and integrated sense of self and others to respond 
to challenges. Unlike the original MAS, the MAS-A is an ordinal scale in which the items of 
each scale describe a more complex metacognitive act than the one before it. Specifically, each 
item of each of the four scales (other than lowest item) requires the integration of a new kind of 
information that was not included in the previous item (e.g. level “4” would require the 
integration of a specific form of information not found in level “3”). Thus, metacognition is 
conceptualized and measured as a series of hierarchical steps. Once a given level is assessed as 
something the participant cannot perform or achieve, then higher levels of integration could also 
not be meaningfully achieved. For example, a person that cannot integrate the information 
described in level 3 of the S scale (forming a sense of one’s mind as involving distinct mental 
activities) is judged to be unable to meaningfully integrate information at any of the higher levels 
of the S scale (e.g. grasping nuanced affects, seeing mental activities as changing, or thinking 
about all of that within the context of a specific narrative episode). Accordingly, the last level 
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achieved on the MAS-A would be conceptualized as the person’s metacognitive capacity with 
lower MAS-A scores suggesting a greater degree of fragmentation in sense of self and others 
available to persons in the moment. Rater training for the MAS-A involves the completion of an 
established set of 16 transcripts followed by supervision.  
Good to excellent levels of interrater reliability have been demonstrated in several studies 
(e.g., Lysaker et al., 2005, 2007), as has acceptable levels of test-retest stability (Hamm et al., 
2012). The MAS-A has also demonstrated good validity across several domains, including 
associations between higher ratings and greater levels of awareness of illness (Lysaker et al., 
2005; Nicolò et al., 2012) as well as better self-appraisal of one’s memory (Fridberg et al., 2010).  
The Spanish version of the IPII along with the MAS-A codebook for scoring metacognition were 
used with the Chilean sample (Lysaker et al., 2016). 
2.2.3. Interpersonal Reactivity Index (IRI; Davis, 1983). The IRI is a self-report measure 
of both cognitive and emotional empathy. It consists of 28 items; participants rate how well each 
item describes them using a five-point Likert scale (1 to 5, higher ratings indicate a greater 
degree of self-reported empathy). The 28 items yield four subscales: Perspective Taking (the 
tendency to take another’s point of view), Empathic Concern (feelings of sympathy and concern 
for others), Fantasy (the ability to imagine oneself in the role of a fictitious character), and 
Personal Distress (feelings of anxiety and apprehension in interpersonal settings). It has 
demonstrated adequate internal consistency and validity in a Chilean sample of college students 
(Fernández et al., 2012).  
 2.2.4. Positive and Negative Syndrome Scale (PANSS; Kay, 1987). The PANSS assesses 
positive and negative symptoms of schizophrenia as well as general symptoms of 
psychopathology. It is a 30-item scale and items are rated on a scale of 1 (absent) to 7 (severe). 
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In the present study, the five-factor solution (Bell et al., 1994) was used to examine the degree of 
symptomatology across five symptom components: Positive, Negative, Cognitive, 
Excitement/Hostility, and Emotional Discomfort.  
2.3. Procedures 
 All procedures were approved by the local ethics committee at the Psychiatric Institute of 
Santiago de Chile. Following informed consent and evaluation of inclusion and exclusion criteria, 
diagnoses were confirmed by senior clinicians, according to non-structured clinical interviews 
and after staff meetings. The IPII and the PANSS were completed by a trained interviewer with a 
medical degree who was currently a resident at the Specialization Programme in Adult 
Psychiatry at a local university. IPII interviews were later transcribed and then rated by trained 
raters who had received formal training of the MAS-A by one of the authors of the original 
MAS-A; they were blind to other test scores and did not conduct or transcribe the interview. 
PANSS ratings were performed blind to MAS-A scores. 
2.4 Data Analysis 
 Analyses were conducted in five steps using SPSS version 24. First, we compared the 
demographic characteristics of the three groups as well as psychiatric symptoms as measured by 
the PANSS for the two clinical groups to determine if these needed to be included as covariates. 
Second, we correlated with MAS-A and IRI scores. Third, we compared groups on the MAS-A 
and the IRI, controlling for potentially relevant covariates. Fourth, we calculated Spearman 
correlations to explore whether metacognition and levels of empathy were related to 
symptomatology in the two clinical groups. Spearman correlations were used given scores were 
not expected to be normally distributed. Fifth, in cases in which both the IRI and MAS-A scores 
were associated with symptoms we planned to perform stepwise regression in which the IRI 
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subscales were forced to enter first, in order to determine whether the link of MAS-A scores with 
symptoms was independent of the effects of trait empathy. 
3. Results 
 The means and standard deviations of participant demographic characteristics as well as 
the PANSS scores for the two clinical groups are reported in Table 1. ANOVAs indicated that 
the control group was significantly younger and also had significantly more education than both 
of the clinical groups. The majority of the schizophrenia spectrum group identified as male and 
had the highest percentage of single unmarried people, while the control group had the greatest 
percentage of employed individuals. The schizophrenia group also had significantly higher levels 
of symptoms than did the bipolar group on all PANSS subscales (Table 1). Follow-up analyses 
revealed that differences in symptom severity persisted after accounting for gender differences 
between the groups. 
 In the next step the MAS-A and IRI scores were correlated in the schizophrenia, bipolar 
and community control groups separately and no significant correlations were found. Given their 
independence we compared both the MAS-A and IRI scores between all three groups controlling 
for age and education using ANCOVA. As indicated in Table 2, the schizophrenia group had 
significantly lower MAS-A subscale and total scores than both the bipolar and community 
control groups. No differences were found for any IRI subscale between groups. Given the 
schizophrenia group had higher ratings of symptoms, we repeated the ANCOVA comparing the 
MAS-A scores between the bipolar and schizophrenia group this time controlling for the PANSS 
total score.  In this analysis, groups continued to differ on self-reflectivity, decentration and the 
total MAS-A score, while differences between groups on mastery and awareness of the other 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
 
12 
were reduced to trend level significance. The MAS-A scores of the bipolar and control groups 
were not significantly different. 
Finally, PANSS subscale scores were correlated with the MAS-A and IRI scores for the 
schizophrenia and bipolar groups. As indicated in Table 3, in the schizophrenia group, cognitive 
and negative PANSS symptoms were broadly correlated with MAS-A scores, while positive and 
emotional discomfort scores were more sporadically linked with MAS-A scores. In the bipolar 
group, excitement scores were broadly correlated with MAS-A scores while cognitive symptoms 
scores were more sporadically linked with MAS-A scores. For both the schizophrenia and 
bipolar disorder groups, the IRI Personal Distress subscale was related to the PANSS negative 
and emotional discomfort factors and the IRI Perspective Taking subscale was related to PANSS 
negative symptoms. Given that specific IRI and MAS-A subscales were both related to the 
PANSS negative and emotional discomfort subscales in the schizophrenia group, we finally 
conducted two stepwise regressions to determine whether the IRI and MAS-A had unique or 
overlapping relationships to these symptoms. Specifically, the IRI variables were allowed to 
enter in the first step and the MAS-A variables in the second step. These revealed that after the 
Personal Distress and Perspective Taking subscales of the IRI accounted for 41% of the variance 
in negative symptoms, and the MAS-A subscales of awareness of the other, mastery, as well as 
the total, significantly accounted for another 36% of the variance (F(3, 22)=10.21; p<0.001). In 
the case of emotional discomfort symptoms, the Personal Distress and Perspective Taking 
subscales accounted for 51% of the variance. The decentration subscale of the MAS-A 
significantly accounted for another 10% of the variance (F(3, 25)=4.391, p=0.14). 
4. Discussion 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
 
13 
 In this study we sought to examine the relative magnitude of metacognitive deficits in 
patients with schizophrenia, bipolar disorder and community controls without a major mental 
health condition, in a sample from a culture not previously studied. Consistent with initial 
predictions, we found that the MAS-A profiles of the schizophrenia patients suggested 
significantly poorer metacognitive function than the other two groups after controlling for 
demographic differences (i.e., age and education level). The schizophrenia group was 
significantly more symptomatic than the bipolar group; when symptom severity was controlled 
for, the schizophrenia and bipolar group continued to differ on overall metacognition as well as 
self-reflectivity and decentration, though not awareness of the other or mastery.  
Findings thus replicate previous English language studies (Lysaker et al., 2013; Lysaker 
et al., 2014; 2017) as well as Italian (Nicolò et al., 2012; Popolo et al., 2017), Danish (Trauelsen 
et al., 2016), German (Bröcker et al., 2017); Chinese (WeiMing et al., 2015a), Turkish (Tas et al., 
2014), Spanish (Inchaustiet al., 2017a; 2017b) and Hebrew (Hasson-Ohayon et al., 2015) 
language studies in a Spanish speaking group in Chile. This study thus adds to the literature that 
suggests that metacognitive deficits in schizophrenia can be detected cross-culturally. While this 
is not to say that metacognition is not affected by culture or language, it does suggest that the 
fundamental difficulties with integrating information into complex ideas about the self and others 
may be an aspect of schizophrenia in many different parts of the globe. 
Concerning the psychosocial significance of differences between the clinical groups, the 
schizophrenia group was generally aware of their own emotional states, but struggled to perceive 
how those changed overtime and to see their own thoughts as subjective and fallible. They could 
perceive others had their own mental states but failed to be able to fully distinguish different 
emotional states in others; they could also see others had their own purposes in life but struggled 
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to see that others had their own valid and different perspectives on life events. Finally, they were 
able to frame a plausible psychological problem they were facing and could seek out support but 
were unable to take behavioral steps to effectively cope with that problem. Of note, these scores 
are somewhat higher than those reported in a Spanish sample from Spain (Inchausti et a., 2017a; 
2017b). This may reflect a slight cultural difference, though it could also be the result of 
recruitment differences, as the samples from Spain were in part derived from a clinical trial. It 
may also reflect the use of a different interview, as the studies in Spain utilized one that was 
more present focused. 
This paper secondarily sought to replicate previous findings linking metacognition with 
two specific forms of psychopathology: negative and cognitive, or disorganization, symptoms in 
schizophrenia. Findings largely confirmed these hypotheses. Greater levels of both negative and 
cognitive symptoms, as well as overall level of symptomatology, were associated with poorer 
overall metacognition as well as lesser abilities to think about the minds of other people and use 
metacognitive knowledge to respond to problems. Cognitive symptoms and overall 
symptomatology were also associated with lesser abilities to self-reflect. Taken as a whole, these 
findings are consistent with phenomenological observations that many individuals with 
schizophrenia experience a loss of agency secondary to the loss of their ability to take into 
account multiple viewpoints, which allows for the self to be perceived as not strictly determined 
by the past or the will of others (Stanghellini, 2016).  It is also consistent with literature 
suggesting negative symptoms are not primary phenomena, but consequences of interpersonal 
difficulties rooted in failures to make sense of others’ behavior both on perceptive-intuitive and 
reflective levels (Stanghellini & Ballerini, 2002; 2011a; 2011b).  
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Of note, our measure of social cognition, emotional reactivity, was also related to 
negative symptoms though not to metacognition, and the relationship of metacognition to 
negative symptoms was partially independent of the relationship of emotional reactivity or trait 
level empathy to negative symptoms. Finding thus replicate previously North American (Lysaker 
et al., 2013; 2015), and Scottish (McLeod et al., 2014) English language findings as well as 
Italian (Popolo et al., 2017), Danish (Trauelsen et al., 2016), Chinese (WeiMing et al.,  2015b), 
Turkish (Tas et al., 2014) and Hebrew (Hasson-Ohayon et al., 2015) language studies suggesting 
metacognitive deficits are related to psychopathology in schizophrenia cross-culturally and can 
be separated from other social cognitive abilities.   
There were unexpected findings. The bipolar group displayed metacognitive abilities 
similar to the community controls. This contradicts the findings of Popolo et al. (2017) and Tas 
et al. (2014). This may indicate that metacognitive capacities in this group are more variable or 
potentially state dependent. For example, during periods of low distress they may be better able 
to form integrated ideas about the self and others. The bipolar group also showed a unique 
pattern of significant correlations between excitement symptoms and metacognition, one not 
found in the schizophrenia group. This may suggest that psychopathology in bipolar disorder has 
a different kind of relationship to metacognition than what is found in schizophrenia.. Finally, 
groups did not differ on the IRI. This contradicts previous findings suggesting social cognitive 
deficits distinguish schizophrenia from bipolar and healthy controls (Bora et al., 2016a; 2016b). 
As with all unexpected and negative findings, any interpretation of them should be considered as 
speculative and fodder for future research.  
There are limitations. The sample size was modest and clinical samples were drawn from 
individuals enrolled in treatment who then consented to this study. It is thus not clear how 
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generalizable results are to other groups including persons who refuse treatment or decline to 
participate in research. The cross-sectional nature of the study further precludes drawing any 
conclusions regarding causality and thus the nature of the relationship of metacognition and 
symptoms cannot be assessed. Additionally, factors not assessed here may contribute to the 
phenomena observed, including years of and stage of illness. Future research should consider 
comparing various groups of patients (e.g., early versus chronic illness) to determine if these 
differences exist. We also utilized only one measure of social cognition, a measure of trait-level 
empathy. Future research is needed which includes broader samples, longitudinal designs and a 
fuller battery of assessments.  
Our measure of empathy, the IRI, was also a self-report measure. Others have suggested 
that these types of measures are limited, as they may not be accurate representations of empathic 
abilities in real-life situations (Derntl et al., 2009). The lack of correlation between the MAS-A 
and the IRI also suggest that metacognitive or mentalizing deficits in the schizophrenia sample 
may prevent individuals from accurately reporting on their mental state. Indeed, people with 
schizophrenia have been found to incorrectly assess their own ability to empathize with others 
(Lee et al., 2011). Future studies should consider using behavioral or performance-based 
instruments (e.g., Smith et al., 2013) to further investigate the potential relationship between 
empathy and the MAS-A.  
Concerning the MAS-A scores, as in other studies, raters could not be fully blinded to 
condition as the content of the IPII and PANSS interviews often clearly contained evidence of 
the patient’s clinical condition. The IPII also asks persons without serious mental illness about 
situations which may be less prolonged and severe; as such, responses may differ given what 
information is elicited from persons with and without serious mental illness. Thus, future 
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research is needed with more attention paid to blinded raters and perhaps more generic stimuli. 
Finally, our correlational analyses contained multiple correlations among groups with a small 
sample size. Thus, there was not adequate power to control for the full number of correlations 
performed and the possibility of spurious findings cannot be ruled out. Future research is needed 
with far larger samples and more stringent statistical controls.  
With future replications in Spanish speaking and other samples, results may have 
important implications. If metacognitive capacities are a barrier to recovery cross-culturally, 
integrative interventions that target metacognition, including Metacognitive Reflection and 
Insight Therapy (MERIT; Lysaker and Klion, 2017), originally designed for English speaking 
patients, may be valuable on an international basis. Indeed, evidence exists that these kinds of 
interventions can be accepted by Dutch (de Jong et al., 2016), French (Dubreucq et al., 2016) and 
Hebrew (Hasson-Ohayon et al., 2017b) speaking patients as well as English speaking patients in 
Australia (Bargenquast and Schweitzer, 2013) with psychosis.  
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Table 1 
Comparisons of group demographics and symptom levels. 
  1 
Schizophrenia 
Spectrum  
(n=26) 
2 
Bipolar 
Disorder  
(n=26) 
3 
Control 
 
(n=36) 
F 
ANOVA 
 
 
Post-Hoc 
Comparisons  
 
Χ2 
 
 
Demographics Age (M, SD) 40.88 (11.99) 44.12 (13.53) 34.17 (7.37) 6.83** 3<1*,2***  
 Gender (male/female) 19/7 8/18 11/25   13.44*** 
 Marital Status (% single) 76.9 34.6 58.3   16.88** 
 Education (M, SD) 12.32 (1.70) 15.46 (1.07) 15.61 (1.15) 53.09*** 1<2,3***  
 Job Status (% employed) 26.9 50 94.4   32.84*** 
  
  
 F 
ANCOVA
1 
  
Positive and 
Negative 
Syndrome 
Scale 
Positive 16.35 (4.95) 7.65 (2.38)  45.72***   
Negative 24.50 (4.47) 11.27 (5.48)  75.42***   
Cognitve 22.58 (4.64) 10.08 (4.23)  84.25***   
Excitement 8.62 (2.00) 5.12 (1.77)  37.19***   
 Emotional Discomfort 11.12 (2.98) 9.08 (4.34)  3.91
+ 
  
 Total 83.15 (11.33) 43.19 (12.78)  113.47***   
+
p=0.054; *p< 0.05; **p<0.01; *** p≤0.001; 1controlling for gender. 
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Table 2 
Comparisons between the groups on the MAS-A and the IRI. 
  1 
Schizophrenia 
Spectrum  
2 
Bipolar 
Disorder  
3 
Control 
 
F 
ANCOVA
1 
 
Post-Hoc 
Comparisons  
 
Metacognition 
Assessment 
Scale 
Abbreviated 
 
Self-reflectivity 4.60 (1.83) 8.46 (0.92) 8.85 (0.39) 36.01***
2 
1<2,3*** 
Awareness of other 3.69 (1.45) 6.39 (1.01) 6.83 (0.34) 24.86***
 
1<2,3*** 
Decentration 1.44 (0.89) 2.87 (0.39) 3.00 (0.00) 25.21***
2 
1<2,3*** 
 Mastery 4.62 (1.79) 8.29 (1.12) 8.32 (1.49) 14.77***
 
1<2,3*** 
 Total 14.35 (5.25) 26.00 (2.86) 27.00 (1.70) 35.72***
2 
1<2,3*** 
       
Interpersonal 
Reactivity 
Index 
Perspective Taking 22.19 (6.29) 22.96 (5.19) 24.08 (4.02) 0.68  
Empathic Concern 26.08 (3.95) 26.70 (4.73) 27.32 (4.99) 0.68  
Personal Distress 19.92 (5.72) 20.19 (5.18) 17.84 (3.91) 1.97  
 Fantasy 19.92 (5.18) 20.15 (5.43) 20.14 (4.86) 0.12  
*p < 0.05; ** p <0.01; *** p <0.001; 
1
 controlling for age and education; 
2
group differences for Self, Decentration and Total remain 
significant at the p < .05 level after adding the PANSS Total score as an additional covariate. 
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Table 3 
Spearman correlations of the MAS-A and the IRI with the PANSS in the patient samples. 
 
Schizophrenia Spectrum Disorder 
(n=26) 
  Bipolar Disorder 
(n=26) 
   
 PANSS Subscales    
MAS-A  Pos Neg Cog Exc ED Total Pos Neg Cog Exc ED Total 
Self-reflectivity -0.35 -0.37 -0.55** -0.13 0.29 -0.50** -0.19 -0.20 -0.26 -0.49* 0.21 -0.13 
Awareness of 
the other 
-0.36 -0.52** -0.44* -0.03 0.26 -0.47* -0.30 -0.26 -0.31 -0.62** 0.19 -0.18 
Decentration -0.42* -0.24 -0.22 -0.24 -0.45* -0.25 -0.18 -0.03 -0.10 -0.25 0.21 0.13 
Mastery  -0.31 -0.70** -0.57** -0.24 -0.04 -0.68** -0.13 -0.23 -0.43* -0.48* 0.18 -0.26 
Total -0.39* -0.54** -0.55** -0.17 0.25 -0.57** -0.24 -0.20 -0.39* -0.56** 0.11 -0.23 
IRI              
Perspective 
Taking 
0.06 -0.41* -0.02 -0.07 -0.58** -0.26 0.02 -0.48* 0.13 -0.06 -0.28 -0.09 
Emapthic 
Concern 
0.10 -0.12 -0.06 -0.26 -0.29 -0.09 0.07 -0.15 -0.04 0.09 -0.29 -0.23 
Personal 
Distress 
0.03 0.48* -0.08 -0.08 0.45* 0.31 -0.11 0.40* -0.15 -0.22 0.51** 0.14 
Fantasy -0.11 0.23 -0.11 0.29 -0.06 -0.02 -0.15 0.06 -0.18 -0.03 -0.07 -0.14 
Pos=Positive; Neg=Negative; Cog=Cognitive; Exc=Excitement/Hostility; ED=Emotional Discomfort; *p < 0.05; **p < 0.01. 
